Use of gemcitabine–platinum in Indian patients with advanced gall bladder cancer. (April 2015)

• Record Type: Journal Article
• Authors: Sirohi, Bhawna; Rastogi, Sameer; Singh, Ashish; Sheth, Vipul; Dawood, Shaheenah; Talole, Sanjay; Ramadwar, Mukta; Kulkarni, Suyash; Shrikhande, Shailesh V
• Is Part Of: Future oncology. Volume 11:Number 8(2015)
• Page Start: 1191
• Page End: 1200
• Publication Date: 2015-04
• Subjects: advanced -- chemotherapy -- gall bladder cancer -- gemcitabine–platinum; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.14.295
• Languages: English
• ISSNs: 1479-6694

Abstract

ABSTRACT : Background: Gemcitabine–platinum (Gem-P) is the current standard for patients with advanced gall bladder cancer.Materials & methods: This is retrospective analysis of a prospectively maintained database of 210 patients with advanced gall bladder cancer treated with Gem-P between January 2012 and September 2013.Results: Median age was 53 years, 65.2% females. In total, 158 patients had metastatic and 52 had locoregional disease. Median number of cycles was 5 (1–12). At a median follow-up of 10 months, median overall survival/progression-free survival was 10/5 months, respectively. On multivariate analysis, patients who underwent prior surgery for primary and locoregional disease had a significantly better progression-free survival and those with locoregional disease had a significantly better overall survival. A total of 45.7% received second-line chemotherapy.Conclusion: Use of Gem-P in Indian patients leads to slightly worse outcomes suggesting an aggressive biology.